Literature DB >> 19525413

Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment.

S Nishida, K Hagihara, Y Shima, M Kawai, Y Kuwahara, J Arimitsu, T Hirano, M Narazaki, A Ogata, K Yoshizaki, I Kawase, T Kishimoto, T Tanaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19525413     DOI： 10.1136/ard.2008.099267

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  13 in total

Review 1.  A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Authors:  Andrea Rubbert-Roth; Daniel E Furst; Jan Michael Nebesky; Angela Jin; Erhan Berber
Journal:  Rheumatol Ther       Date:  2018-03-03

2.  Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis.

Authors:  Daichi Inoue; Hiroshi Arima; Chiharu Kawanami; Yoko Takiuchi; Seiji Nagano; Takaharu Kimura; Sonoko Shimoji; Minako Mori; Sumie Tabata; Soshi Yanagita; Akiko Matsushita; Kenichi Nagai; Yukihiro Imai; Takayuki Takahashi
Journal:  Clin Rheumatol       Date:  2010-03-15       Impact factor: 2.980

Review 3.  [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].

Authors:  C Iking-Konert; P Bartz-Bazzanella; D Falagan; M W Hofman; A Schwarting; T Dörner
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

4.  Diagnosis of amyloidosis and differentiation from chronic, idiopathic enterocolitis in rhesus (Macaca mulatta) and pig-tailed (M. nemestrina) macaques.

Authors:  Kelly A Rice; Edward S Chen; Kelly A Metcalf Pate; Eric K Hutchinson; Robert J Adams
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

5.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

6.  Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome - effective treatment with tocilizumab.

Authors:  Małgorzata Kwiatkowska; Ewa Jednacz; Lidia Rutkowska-Sak
Journal:  Reumatologia       Date:  2015-08-07

Review 7.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580

Review 8.  Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors.

Authors:  Toshio Tanaka; Yoshihiro Hishitani; Atsushi Ogata
Journal:  Biologics       Date:  2014-04-07

9.  Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis.

Authors:  Masaru Matsui; Satoshi Okayama; Hideo Tsushima; Kenichi Samejima; Tomoko Kanki; Ayako Hasegawa; Katsuhiko Morimoto; Yasuhiro Akai; Masato Takano; Shiro Uemura; Chiho Ohbayashi; Yoshihiko Saito
Journal:  Case Rep Nephrol       Date:  2014-08-12

Review 10.  Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Authors:  Maria Gabriella Raimondo; Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Ennio Giulio Favalli
Journal:  Drug Des Devel Ther       Date:  2017-05-24       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.